Sharemaestro Newsreel

Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis

Neurocrine Biosciences Inc (NBIX) currently holds a financial score of 8.50, placing it 50th out of 155 companies in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 42.25% to $814.50 million and …

Lifecore Biomedical Inc (LFCR) Financial Health: Profitability & Balance Sheet Analysis

Lifecore Biomedical Inc (LFCR) currently holds a weak financial score of 6.79 out of 10, ranking 134th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 6.12% and a net profit decrease of 1.82% in …

Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Emergent BioSolutions Inc (EBS), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It shows that EBS has a price momentum score of 3.62, trading between a resistance of 8.22 and support …

Cumberland Pharmaceuticals Inc (CPIX) Financial Health: Profitability & Balance Sheet Analysis

Cumberland Pharmaceuticals Inc (CPIX) has a financial score of 7.53, ranking 110 out of 155 in the pharmaceuticals industry, indicating stable financial status and high operating efficiency. Despite this, its latest quarterly revenue decreased by 22.04% year-over-year, and net profit saw a significant 361.69% …

Viatris Number of Employees 2026 | Employee Count & Headcount Data

Viatris, Inc. (NASDAQ: VTRS) reported approximately 29,935 global employees as of March 2026, marking a 3.8% decline from 2023. The company is actively hiring with 474 open job postings in 2026, a 10.7% increase from 2025. Viatris's workforce is primarily located in India (43.1%), …

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

(RTTNews) - Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue outlook on strong commercial momentum; and MapLight Therapeutics, which staged a sharp …

Neurocrine Biosciences, Inc. Revenue Breakdown – BX:NB3

Neurocrine Biosciences, Inc. (BX:NB3) reported a total revenue of 2.27 billion CHF last year, primarily driven by its Pharmaceuticals segment. The majority of this revenue, also 2.27 billion CHF, came from operations within the United States. This indicates a strong reliance on the pharmaceutical …

Emergent BioSolutions | SCHEDULE 13G/A: Others

This article is a SCHEDULE 13G/A filing related to Emergent BioSolutions. It indicates an amendment to a previous filing, typically involving changes in beneficial ownership of the company's stock by a significant investor.

Bausch Health Companies Inc (BHC) Risk Assessment: Volatility, Financial Risk & Investment Risk

Bausch Health Companies Inc (BHC) has a current risk assessment score of 6.07, ranking 59 out of 155 in the Pharmaceuticals industry. The company's beta value of 0.42 indicates it may underperform during bull markets but experience smaller declines during bear markets. The report …

Cronos Group Inc (CRON) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cronos Group Inc (CRON), focusing on its price momentum, support, and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, offering insights into potential buy, sell, or neutral signals. The analysis suggests CRON …

KMDA|Kamada Ltd|Price:7.070|Chg%:+0.080

This article provides a detailed stock analysis for Kamada Ltd (KMDA), highlighting its current market trends, financial performance, and analyst ratings. Based on three analysts, the stock has a "Buy" rating with a target price of $13.00, representing an 84.14% upside. While Kamada Ltd …

OGI|OrganiGram Holdings Inc|Price:0.929|Chg%:-0.019

This article provides a comprehensive stock analysis of OrganiGram Holdings Inc (OGI) by TradingKey, assigning it a score of 4.59 out of 10. The analysis highlights the company's significant growth potential, stable fundamentals, and fair valuation, despite recent weak market performance. It also details …

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS) The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how generic pharmaceuticals stocks fared in Q1, starting with …

Biofrontera Inc. Revenue Breakdown – NASDAQ:BFRI

Biofrontera Inc. (NASDAQ: BFRI) generated $41.70 million in revenue last year, primarily from its Pharmaceutical Products segment. This revenue marks an increase from $37.32 million in the previous year. The United States was the company's sole significant regional contributor, accounting for all reported revenue.

Cumberland Pharmaceuticals Q2 Results: Company update and earnings call set for Aug 4

Cumberland Pharmaceuticals Inc. will release its Q2 2026 financial results and provide a company update on August 4, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results, with a replay available for one year. The company …

Collegium Pharmaceutical, Inc. $COLL Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC reduced its stake in Collegium Pharmaceutical (NASDAQ:COLL) by 9.1% in the first quarter, selling 147,900 shares but still owning 1.47 million shares valued at $48.6 million. Despite this sale, other institutional investors increased their holdings, and the company reported strong Q1 …

Tilray rises despite missing FQ4 bottom line on strong FY27 EBITDA growth guidance

[Fourth Quarter Q4 Profits Stock Trading Chart 3D Background] * Tilray Brands (TLRY [https://seekingalpha.com/symbol/TLRY]) is up ~3% in after-hours trading Tuesday after its FQ4 EPS results missed [https://seekingalpha.com/news/4619781-tilray-non-gaap-eps-of-0_11-misses-by-0_10-revenue-of-281_71m-beats-by-35_41m] expectations as its full-year EBITDA guidance of $68M-$75M represents double-digit year-over-year growth. * Though a miss, …

United Therapeutics CEO Rothblatt sells $5 million in shares

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares for approximately $5 million on July 28, 2026, after exercising stock options. This transaction was part of a pre-arranged 10b5-1 trading plan adopted in November 2025. Despite the insider sale, the company has …

Form 4 United Therapeutics Corporation For: 28 July By Investing.com

The article reports on a Form 4 filing for United Therapeutics Corporation (UTHR) which was made on July 28. It provides minimal details about the filing itself, primarily serving as an announcement of the document's existence rather than offering insights into its content. The …

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High - What's Next?

Eton Pharmaceuticals (NASDAQ:ETON) recently hit a new 52-week high of $45.27, trading near $44.91, following a consensus "Moderate Buy" rating and an average price target of $52.50 from analysts. Despite beating revenue expectations, the company missed EPS estimates in its latest quarter, and insiders …

EcoR1 Capital LLC Purchases 141,394 Shares of Eton Pharmaceuticals, Inc. $ETON

EcoR1 Capital LLC has increased its stake in Eton Pharmaceuticals (NASDAQ:ETON) by 7%, purchasing an additional 141,394 shares to own 7.93% of the company, valued at approximately $53.6 million. Despite a "Moderate Buy" consensus rating and a $45.75 target price from analysts, company insiders …

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $29.32, demonstrating a -3.04% change from the preceding day's closing price. This change lagged the S&P 500's 0.21% gain on the day. Elsewhere, the Dow gained 1.03%, while the tech-heavy Nasdaq lost …

Form 4 Elanco Animal Health For: 28 July By Investing.com

This Investing.com article reports on a Form 4 filing for Elanco Animal Health for July 28. It includes the company's stock symbol ELAN and notes its current performance with a slight increase. The article provides a brief update on insider transaction filings for the …

Elanco Animal Health Inc (NYSE: ELAN) awards deferred stock units

Elanco Animal Health Inc (NYSE: ELAN) reported that EVP Rajeev A. Modi was granted 59.2906 deferred stock units on July 24, 2026, with a reference value of $24.91 per unit. These units, which represent the right to receive one share of common stock or …

BlackRock (ETON stakeholder) reports 6.9% ownership in Eton Pharmaceuticals common stock

BlackRock, Inc. has filed an amended Schedule 13G/A report indicating a beneficial ownership of 1,882,410 shares of Eton Pharmaceuticals, Inc. common stock, which represents 6.9% of the outstanding class as of June 30, 2026. The filing shows BlackRock holds sole voting power over 1,850,186 …

Stronger Q2 Results And Higher 2026 Outlook Might Change The Case For Investing In Kiniksa (KNSA)

Tilray Brands Releases Q4 2026 Financial Results

Tilray Brands, Inc. reported mixed financial results for Q4 2026, with adjusted earnings per share missing analyst estimates at $0.05 against an expected $0.21, representing a 76.2% miss. However, the company's revenue exceeded expectations, reaching $281.7 million, a 14.4% beat over the consensus and …

BlackRock, Inc. (NASDAQ: IRWD) discloses 8.1% beneficial stake in Ironwood

BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in Ironwood Pharmaceuticals Inc, totaling 13,373,568 shares of Class A stock. BlackRock exercises sole voting power over 13,195,313 shares and sole dispositive power over all 13,373,568 shares. The filing specifies …

Lantheus Holdings, Inc. Stock 12‑Month Price Target Raised to $113.82, Implies 5% Upside

Lantheus Holdings, Inc. (LNTH) has seen its average 12-month price target raised to $113.82 by 11 analysts, up from $112.91. This new target suggests a potential 5% upside based on the July 27 closing price. The consensus analyst rating remains a "Buy" across 14 …

BCRX|BioCryst Pharmaceuticals Inc|Price:9.609|Chg%:-0.131

This article provides a comprehensive stock analysis of BioCryst Pharmaceuticals Inc (BCRX), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes strong institutional ownership, a consensus "Buy" rating from analysts with a …

Cumberland's ifetroban is in Phase 2 studies for four diseases

Cumberland Pharmaceuticals (Nasdaq: CPIX) announced it will release its Q2 2026 financial results and a company update on Tuesday, August 4, 2026, after market close, followed by a conference call. The Tennessee-based biopharmaceutical company is focused on rare diseases and is progressing its late-stage …

Phibro shareholders set to receive $0.12 dividend Sept. 23

Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. The dividend is payable on September 23, 2026, to stockholders of record as of September 2, 2026. Phibro Animal Health is a …

Phibro Animal Health declares $0.12 quarterly dividend payable Sept. 23

Phibro Animal Health (PAHC) has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend is payable on September 23, 2026, to shareholders of record as of September 2, 2026. This announcement was filed …

Eton Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ETON

This article provides a revenue breakdown for Eton Pharmaceuticals Inc (ETON), focusing on its business segments and regional contributions. It notes that relevant data for FY2025 and its quarters, as well as FY2024, have not yet been disclosed by the company. However, it does …

Rockwell Medical, Inc. Revenue Breakdown – LSX:A42EKB

Rockwell Medical, Inc. (A42EKB on Lang & Schwarz Exchange) reported a total revenue of €58.97 million last year, down from €97.99 million in the previous year. The majority of this revenue, €58.69 million, was generated from its Concentrate Products segment. The United States was …

Alkermes PLC (ALKS) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst Competitive ...

This article first appeared on GuruFocus. Release Date: July 28, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Alkermes PLC (NASDAQ:ALKS) reported a 34% year-over-year increase in net sales from its proprietary product …